Analystreport

Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com